Can Aspect Biosystems turn government-backed biomanufacturing into a real regenerative medicine advantage?
Aspect Biosystems has secured a $280 million Canada-backed push in regenerative medicine. Read what it means for cellular therapy scale-up.
Pharma & Biotech
Pharma & Biotech
Is deceased donor marrow a viable backup graft? First human data from Ossium says yes
Ossium unveils early data on cryopreserved cadaveric marrow in transplants. Find out what this could mean for urgent graft availability.